37 citations
,
October 2017 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This literature review reported that scalp hypothermia significantly decreases the occurrence of chemotherapy-induced alopecia, increasing effectiveness by 2.7-fold in controlled clinical trials and 3.9-fold in randomized trials, and highlighted a need for standard guidelines for its use.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.
August 2018 in “Journal of The American Academy of Dermatology” Oral alitretinoin is effective for certain types of chronic hand eczema, with mild side effects.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.
December 2025 in “International Journal of Innovative Technologies in Social Science” This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.